Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharma entities : Nuvectis pharma, inc. save search
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 3.64%
H: 4.62%
C: -19.02%
pharma association cancer research meeting
Nuvectis Pharma to Present at the 36th Annual Roth Conference
Published: 2024-03-15 (Crawled : 12:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: -0.55%
H: 24.18%
C: 20.88%
pharma conference
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Published: 2024-03-14 (Crawled : 13:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 22.93%
H: 2.11%
C: -22.78%
nxp800 pharma cancer trial
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences - February 9, 2024
Published: 2024-02-09 (Crawled : 15:30) - biospace.com/
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 1.6%
H: 2.14%
C: -4.43%
pharma
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Published: 2024-02-09 (Crawled : 13:30) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 1.6%
H: 2.14%
C: -4.43%
pharma
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Published: 2024-02-09 (Crawled : 13:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 1.6%
H: 2.14%
C: -4.43%
pharma
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 13:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 0.97%
H: 4.18%
C: -1.08%
pharma conference
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
Published: 2023-10-24 (Crawled : 12:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 0.0%
H: 9.78%
C: 0.33%
nxp800 pharma conference presentation cancer
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
Published: 2023-09-25 (Crawled : 23:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: -2.84%
H: 6.08%
C: 2.63%
pharma conference presentation global
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
Published: 2023-09-21 (Crawled : 12:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: -2.11%
H: 6.93%
C: 2.31%
nxp800 pharma nxp900
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
Published: 2023-09-12 (Crawled : 12:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 0.51%
H: 4.85%
C: 1.67%
nxp900 pharma trial
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET
Published: 2023-09-06 (Crawled : 14:00) - biospace.com/
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: -1.42%
H: 4.68%
C: 1.73%
nxp800 pharma drug
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
Published: 2023-09-06 (Crawled : 12:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: -1.42%
H: 4.68%
C: 1.73%
nxp800 pharma drug nxp900
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Published: 2023-09-01 (Crawled : 12:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 0.45%
H: 5.11%
C: 2.96%
pharma
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
Published: 2023-08-17 (Crawled : 12:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 5.12%
H: 0.0%
C: -3.27%
nxp800 fda pharma drug granted treatment designation
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
Published: 2023-06-20 (Crawled : 12:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 0.77%
H: 0.22%
C: -1.32%
2000 pharma set
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
Published: 2023-05-15 (Crawled : 12:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 2.88%
H: 3.95%
C: 3.22%
nxp900 fda pharma clearance
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
Published: 2023-04-18 (Crawled : 20:00) - biospace.com/
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: 0.0%
H: 0.76%
C: 0.76%
nxp800 pharma association presentation cancer research meeting
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
Published: 2023-04-10 (Crawled : 22:00) - globenewswire.com
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: -1.92%
H: 1.8%
C: 0.78%
nxp800 pharma study
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian CarcinomaPhase 1b study builds on highly consistent preclinical and Phase 1a data
Published: 2023-04-10 (Crawled : 13:20) - biospace.com/
NVCT | $6.715 1.9% 1.86% 51K
|
|
| O: -1.92%
H: 1.8%
C: 0.78%
nxp800 pharma preclinical study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.